Tocilizumab's Potential Therapeutic Effect in the therapy of Endometriosis | ||
Mansoura Journal of Biology | ||
Volume 54, Issue 1, March 2022, Pages 1-5 PDF (720.88 K) | ||
Document Type: Original Article | ||
DOI: 10.21608/mjb.2022.450418 | ||
Authors | ||
Nada Mohamed Fawzy* 1; Ahmed Mahmoud Badawy A2; Ahmed Abdelhamıd Salah El-Zayadi3; Amoura Mohamed Abou-EL-Naga4 | ||
1Facultyof science, Mansoura Unversity | ||
2Prof. of Obsterics & Gynecology, Faculty of Medicine, Mansoura Unıversıty | ||
3A. Prof. of Obsterics & Gynecology, Faculty of Medicine, Mansoura University | ||
4Prof. of Experimental Embryology, Facultyof science, Mansoura University | ||
Abstract | ||
Introduction: Endometriosis is a chronic inflammatory syndrome that typically affects premenopausal women and is characterized by the growth of endometrial tissue and stromal cellbeyond the uterus.Many pro-inflammatory cytokines, particularly tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL8 and monocyte chemotactic protein-1 (MCP-1) play important roles in endometriosis pathogenesis. Materials/ Methods:Endometriosis was studied using 18 of female Sprague rats. Animals were randomly separated into two sets: tocilizumab-treated animals and saline-treated animals.After endometrial tissues volumes were measured, immunohistochemical examination was evaluated. Results:The treated and control groups had similar pretreatment spherical volumes (P>.05). There was a significant change between pretreatment and posttreatment implant volumes after treatment (P<.05).). Also immunohistochemistry technique show differences in immunoreaction intensity for IL6 in control and treated Group. | ||
Keywords | ||
Endometriosis. Cytokines. Interleukin; 6.) | ||
Statistics Article View: 35 PDF Download: 10 |